F10 and deep vein thrombosis: Findings from the multicentre, open-label superiority ONCO DVT trial in patients with cancer and distal deep vein thrombosis (DVT) showed that 12 months of edoxaban (an oral factor Xa inhibitor) is superior to 3 months for the reduction of thrombotic events.